AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23117133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-LH surge
Number of subjects: 25
Study 23117133 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-LH surge
Number of subjects: 25
Study 23117133 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 25
Study 21997940 — intervention group
Group type: EXPERIMENTAL
Intervention: Depilatory cream
Number of subjects: 165
Study 21997940 — intervention group
Group type: COMPARATOR
Intervention: Razor shaving
Number of subjects: 165
Study 18435231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education by health visitor, including dental health advice, toothbrush and toothpaste with 440 ppm fluoride, provided during home visits at ages 8 months and 20 months.
Number of subjects: 501
Study 18435231 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual care from health visitors.
Number of subjects: 501
Study 16586358 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent baculovirus-expressed HA vaccine at 45 microg
Number of subjects: 399
Study 16586358 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent baculovirus-expressed HA vaccine at 135 microg
Number of subjects: 399
Study 16586358 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 399
Study 12719743 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 60
Study 12719743 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction intervention
Number of subjects: 60
Study 12719743 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 10742158 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 0
Study 10742158 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 8816723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20mg at night
Number of subjects: 95
Study 8816723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 1330019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera toxin (15 micrograms or 25 micrograms) administered into a 'closed' jejunal segment
Number of subjects: 0
Study 1330019 — intervention group
Group type: COMPARATOR
Intervention: Cholera toxin administered by mouth with sodium bicarbonate
Number of subjects: 0
Study 1330019 — intervention group
Group type: COMPARATOR
Intervention: Cholera toxin delivered directly into an 'open' jejunal segment
Number of subjects: 0
Study 4043682 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-cm flexible sigmoidoscope
Number of subjects: 258
Study 4043682 — intervention group
Group type: COMPARATOR
Intervention: 60-cm flexible sigmoidoscope
Number of subjects: 258
Study 29670343 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized exercise intervention (N=15)
Number of subjects: 28
Study 29670343 — intervention group
Group type: COMPARATOR
Intervention: Non-periodized exercise intervention (N=13)
Number of subjects: 28
Study 27598679 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous neurostimulation (treatment group)
Number of subjects: 151
Study 27598679 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 151
Study 24247616 — intervention group
Group type: EXPERIMENTAL
Intervention: Varespladib (500 mg daily for 16 weeks)
Number of subjects: 5145
Study 24247616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5145
Study 24247616 — intervention group
Group type: EXPERIMENTAL
Intervention: Varespladib
Number of subjects: 5145
Study 23270291 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno® III - sandblasting
Number of subjects: 30
Study 23270291 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE - sandblasting
Number of subjects: 30
Study 23270291 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE - grinding
Number of subjects: 30
Study 23270291 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE - cleaned only
Number of subjects: 30
Study 23270291 — intervention group
Group type: COMPARATOR
Intervention: Xeno® III - cleaned only
Number of subjects: 30
Study 23270291 — intervention group
Group type: COMPARATOR
Intervention: Xeno® III - grinding
Number of subjects: 30
Study 20537812 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine 20mg bid (N=39)
Number of subjects: 112
Study 20537812 — intervention group
Group type: COMPARATOR
Intervention: placebo (N=42)
Number of subjects: 112
Study 20537812 — intervention group
Group type: COMPARATOR
Intervention: lead-in period (high-value voucher contingency management)
Number of subjects: 112
Study 18675711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAH patients with severe form of the disease
Number of subjects: 54
Study 18675711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAH patients with milder forms of the disorder
Number of subjects: 54
Study 18675711 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced bone age (indicator of long-term childhood exposure to testosterone)
Number of subjects: 54
Study 18675711 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 54
Study 15902990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/kg of NH4Cl (ACD)
Number of subjects: 12
Study 15902990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg of Na+HCO3‐ and 0.2 g/kg of sodium citrate (ALK)
Number of subjects: 12
Study 15902990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium carbonate) (PLAC)
Number of subjects: 12
Study 11487536 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (3 mg/kg infusion)
Number of subjects: 30
Study 11487536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9620569 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric assessment
Number of subjects: 776
Study 9620569 — intervention group
Group type: EXPERIMENTAL
Intervention: Health visitor questionnaire
Number of subjects: 776
Study 9620569 — intervention group
Group type: COMPARATOR
Intervention: Paediatric assessment vs Health visitor questionnaire
Number of subjects: 776
Study 9620569 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial endpoint
Number of subjects: 776
Study 8026943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 10
Study 8026943 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 10
Study 2692553 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural control procedures
Number of subjects: 27
Study 2692553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control methods (distraction)
Number of subjects: 27
Study 2692553 — intervention group
Group type: COMPARATOR
Intervention: Untreated control subjects
Number of subjects: 27
Study 31994643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% naproxen patches
Number of subjects: 30
Study 31994643 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 30
Study 26997317 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Being Me Co‐educational intervention delivered in single-sex classes (n=74)
Number of subjects: 200
Study 26997317 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Being Me Co‐educational intervention delivered in co-educational classes (n=73)
Number of subjects: 200
Study 26997317 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group (n=53)
Number of subjects: 200
Study 24990390 — intervention group
Group type: EXPERIMENTAL
Intervention: low protein diet + prebiotic + probiotic supplementation (N=12)
Number of subjects: 24
Study 24990390 — intervention group
Group type: COMPARATOR
Intervention: low protein diet only (N=12)
Number of subjects: 24
Study 24996984 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL-directed therapy
Number of subjects: 0
Study 24996984 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 21903347 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups (RMCs)
Number of subjects: 446
Study 21903347 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 446
Study 18633127 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day (stage 1)
Number of subjects: 65
Study 18633127 — intervention group
Group type: COMPARATOR
Intervention: Benzbromarone 100 mg/day (stage 1)
Number of subjects: 65
Study 18633127 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/day (stage 2)
Number of subjects: 65
Study 18633127 — intervention group
Group type: COMPARATOR
Intervention: Benzbromarone 200 mg/day (stage 2)
Number of subjects: 65
Study 17353072 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS)
Number of subjects: 309
Study 17353072 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 309
Study 17353072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 15155715 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained (ET) subjects
Number of subjects: 0
Study 15155715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontrained (NT) women
Number of subjects: 0
Study 15155715 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after a 90-min exercise bout
Number of subjects: 0
Study 15155715 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained (ET) men
Number of subjects: 0
Study 15155715 — intervention group
Group type: COMPARATOR
Intervention: Nontrained (NT) subjects
Number of subjects: 0
Study 11250852 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual educational visits
Number of subjects: 240000
Study 11250852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group educational visits
Number of subjects: 240000
Study 11250852 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 240000
Study 9498508 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (25 to 49 U/h for 7 days)
Number of subjects: 6
Study 9498508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7988265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural chemotherapy with cisplatin (100 mg/m2) and cytarabine (1,200 mg)
Number of subjects: 46
Study 7988265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural chemotherapy with cisplatin and cytarabine
Number of subjects: 46
Study 2919139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant (surfactant TA, Tokyo Tanabe Co, Tokyo)
Number of subjects: 41
Study 2919139 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 41
Study 2919139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant mixed with technetium‐99m sulfur colloid
Number of subjects: 41
Study 29710099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education combined with cognition-targeted motor control training
Number of subjects: 120
Study 28145413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovaza (omega-3 preparation)
Number of subjects: 0
Study 28145413 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study 26130341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chrome (CoCr) femoral head and highly cross-linked polyethylene (XLPE) liner
Number of subjects: 368
Study 26130341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidised zirconium (OxZi) femoral head and XLPE liner
Number of subjects: 368
Study 26130341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidised zirconium (OxZi) femoral head and ultra-high molecular weight polyethylene (UHMWPE) liner
Number of subjects: 368
Study 26130341 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chrome (CoCr) with XLPE vs OxZi with XLPE
Number of subjects: 368
Study 23446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma trans 18:2 (linoleic acid) fatty acids
Number of subjects: 1576
Study 23446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma trans 16:1 and 18:1 fatty acids
Number of subjects: 1576
Study 23446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary trans fats
Number of subjects: 1576
Study 21054216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) plus current NRTI backbone
Number of subjects: 20
Study 21054216 — intervention group
Group type: COMPARATOR
Intervention: Continuation of current regimen
Number of subjects: 20
Study 21054216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 20
Study 20043831 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activity monitoring and distance counselling (12 months)
Number of subjects: 1100
Study 20043831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 1100
Study 17295588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.60 mg)
Number of subjects: 120
Study 17295588 — intervention group
Group type: COMPARATOR
Intervention: Expectancy (no nicotine)
Number of subjects: 120
Study 17295588 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 120
Study 17295588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.60 mg) and Expectancy
Number of subjects: 120
Study 15582071 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK with Zyoptix 3.1 system
Number of subjects: 97
Study 11506058 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/day phytosterols
Number of subjects: 84
Study 11506058 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 g/day phytosterols
Number of subjects: 84
Study 11506058 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.0 g/day phytosterols
Number of subjects: 84
Study 11506058 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/day phytosterols (control)
Number of subjects: 84
Study 8738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid trials with location cues indicating the target location
Number of subjects: 1280
Study 8738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Invalid trials with location cues indicating the opposite location
Number of subjects: 1280
Study 8738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral cue in gap condition (experiment 1)
Number of subjects: 1280
Study 8738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral cue in overlap condition (experiment 2)
Number of subjects: 1280
Study 8738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Central cue without visual stimulation at peripheral location (experiment 3)
Number of subjects: 1280
Study 8738379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-elicited saccades in response to the cue with target at opposite location
Number of subjects: 1280
Study 2105242 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (3.75 mg IM every 4 weeks for four injections)
Number of subjects: 18
Study 2105242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IM every 4 weeks for four injections)
Number of subjects: 18
Study 7419983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis-generating group (36 subjects)
Number of subjects: 54
Study 7419983 — intervention group
Group type: COMPARATOR
Intervention: Hypothesis-testing group (18 subjects)
Number of subjects: 54
Study 7419983 — intervention group
Group type: EXPERIMENTAL
Intervention: Model parameters (production rate, pool sizes)
Number of subjects: 54
Study 7419983 — intervention group
Group type: EXPERIMENTAL
Intervention: Model parameters (cholesterol mass)
Number of subjects: 54
Study 7419983 — intervention group
Group type: EXPERIMENTAL
Intervention: Model parameters (pool sizes)
Number of subjects: 54
Study 31561712 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure
Number of subjects: 947
Study 31561712 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 947
Study 31561712 — intervention group
Group type: COMPARATOR
Intervention: Climate Schools
Number of subjects: 947
Study 31561712 — intervention group
Group type: COMPARATOR
Intervention: Combined Climate Schools and Preventure (CAP)
Number of subjects: 947
Study 30545915 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IL-1β Abs
Number of subjects: 0
Study 30545915 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 Abs
Number of subjects: 0
Study 30545915 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IL-1β Abs followed by anti-PD-1 Abs
Number of subjects: 0
Study 27060991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT) with silodosin at 8 mg/day and propiverine at 20 mg/day
Number of subjects: 120
Study 27060991 — intervention group
Group type: COMPARATOR
Intervention: α1-blocker monotherapy (MT) with silodosin at 8 mg/day
Number of subjects: 120
Study 25702095 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg tranexamic acid (TXA) in 100 mL normal saline solution
Number of subjects: 92
Study 25702095 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 92
Study 25639139 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat biscuits
Number of subjects: 0
Study 25639139 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean biscuits
Number of subjects: 0
Study 25639139 — intervention group
Group type: COMPARATOR
Intervention: Wheat biscuit (control)
Number of subjects: 0
Study 22711350 — intervention group
Group type: EXPERIMENTAL
Intervention: EPB‐348 2,000 mg once‐daily
Number of subjects: 373
Study 22711350 — intervention group
Group type: EXPERIMENTAL
Intervention: EPB‐348 3,000 mg once‐daily
Number of subjects: 373
Study 22711350 — intervention group
Group type: EXPERIMENTAL
Intervention: EPB‐348 1,000 mg once‐daily
Number of subjects: 373
Study 22711350 — intervention group
Group type: COMPARATOR
Intervention: valacyclovir 1,000 mg 3‐times daily
Number of subjects: 373
Study 20048210 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline (1 mg twice daily)
Number of subjects: 714
Study 20048210 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 714
Study 18478182 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine (300 mg a day)
Number of subjects: 27
Study 18478182 — intervention group
Group type: COMPARATOR
Intervention: famotidine (40 mg a day; control)
Number of subjects: 27
Study 16317825 — intervention group
Group type: EXPERIMENTAL
Intervention: THC:CBD spray (Sativex)
Number of subjects: 368
Study 16317825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 11846320 — intervention group
Group type: EXPERIMENTAL
Intervention: Third extrastimulus introduced during programmed ventricular stimulation (protocol A)
Number of subjects: 94
Study 11846320 — intervention group
Group type: EXPERIMENTAL
Intervention: Third extrastimulus introduced early (protocol B)
Number of subjects: 94
Study 10066995 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for depression over 16 weeks
Number of subjects: 0
Study 10066995 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment depression
Number of subjects: 0
Study 10066995 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month follow-up
Number of subjects: 0
Study 8773419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lea's Shield with spermicide
Number of subjects: 185
Study 8773419 — intervention group
Group type: COMPARATOR
Intervention: Lea's Shield without spermicide
Number of subjects: 185
Study 8773419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lea's Shield (both groups)
Number of subjects: 185
Study 1611645 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 579
Study 1611645 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg thrice daily)
Number of subjects: 579
Study 6360413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine
Number of subjects: 27
Study 6360413 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 27
Study 6360413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31001997 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting no angina (62.3%)
Number of subjects: 1258
Study 31001997 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age, worse preoperative SAQ angina frequency score, smoking, diabetes mellitus, and pre‐CABG depression
Number of subjects: 1258
Study 31001997 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization of the left anterior descending (LAD) territory
Number of subjects: 1258
Study 31001997 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual major coronary artery stenosis of ≥70%
Number of subjects: 1258
Study 31001997 — intervention group
Group type: COMPARATOR
Intervention: Graft occlusions, incomplete revascularization of non‐LAD territories, and ≥70% lesions in nonrevascularized native coronary arteries
Number of subjects: 1258
Study 29178239 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities Mobilizing for Change on Alcohol (CMCA) intervention
Number of subjects: 1399
Study 26872880 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 session alcohol harm reduction intervention
Number of subjects: 818
Study 26872880 — intervention group
Group type: COMPARATOR
Intervention: 6 session non-alcohol related nutrition intervention
Number of subjects: 818
Study 24352294 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (4 hours per night)
Number of subjects: 10
Study 24352294 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (8 hours per night)
Number of subjects: 10
Study 21195592 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain wheat sourdough bread (162.5 g)
Number of subjects: 28
Study 21195592 — intervention group
Group type: COMPARATOR
Intervention: Refined white bread (168.8 g)
Number of subjects: 28
Study 21195592 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain wheat sourdough bread
Number of subjects: 28
Study 21195592 — intervention group
Group type: COMPARATOR
Intervention: Refined white bread
Number of subjects: 28
Study 20718545 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer for the partner over a 6-week period
Number of subjects: 375
Study 20718545 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prayer for 4 weeks
Number of subjects: 375
Study 20718545 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer for the partner for 4 weeks
Number of subjects: 375